TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06237231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIT112
Description: DIT112 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE
Description: Dipyrone tablet 1.000mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL
Description: Tramadol tablet 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIT112 Placebo
Description: DIT112 placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIT112 Placebo
Description: DIT112 placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyrone Placebo
Description: Dipyrone placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone Placebo
Description: Dipyrone placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Placebo
Description: Tramadol placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Placebo
Description: Tramadol placebo capsule
Study: NCT06158165

Intervention type: DEVICE
Intervention: Mostcare (Vytech, Vygon, Padua, Italy)
Description: Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).

Intervention type: DEVICE
Intervention: Mostcare (Vytech, Vygon, Padua, Italy)
Description: Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
Study: NCT05745935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
Study: NCT04780269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Induction of labor with Foley catheter
Description: A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of labor with PGE2
Description: PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
Study: NCT05689931

Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Intervention type: DRUG
Intervention: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Intervention type: DRUG
Intervention: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Intervention type: DRUG
Intervention: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Study: NCT06277752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-5 group
Description: IBI128 300mg po. QD(Quaque Die)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-1 group
Description: IBI128 25mg po. QD(Quaque Die)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-2 group
Description: IBI128 50mg po. QD(Quaque Die)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-4 group
Description: IBI128 200mg po. QD(Quaque Die)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-3 group
Description: IBI128 100mg po. QD(Quaque Die)
Study: NCT04987138

Intervention type: DEVICE
Group type: OTHER
Intervention: Zenflow Spring System
Description: The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.

Intervention type: DEVICE
Group type: OTHER
Intervention: Zenflow Spring System
Description: The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zenflow Spring System
Description: The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
Study: NCT05364411

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)
Description: 20 daily fractions, 5 times per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)
Description: 20 daily fractions, 5 times per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionated radiotherapy
Description: 35 daily fractions, 5 times per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionated radiotherapy
Description: 35 daily fractions, 5 times per week
Study: NCT04857099

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT06538506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehUp BCI Intervention
Description: Participants will be seated wearing a cap on their head containing surface electrodes connected to a computer/laptop. The laptop employs machine learning algorithms and uses the scalp electroencephalogram (EEG) signals from the scalp's surface to control a robotic arm which supports the patient's stroke-affected arm. The machine learning algorithms rapidly interpret EEG signals and adjust the outgoing movement commands to the robot based on an individual's responses to stimuli. The participant will be wearing a VR headset. The VR displays visual stimulus in time with the robotic arm. Based on information from the EEG, the participant is able to animate their robotic arm and receive visual task-based feedback in the VR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: The study therapist will focus on 3 activities (\~15 minutes each/session): passive range of motion exercises, motor imagery, and mirror therapy. These activities were chosen as they are all passive activities that are commonly used in a patient with severe impairment of the post-stroke arm and hand. Each session will last \~1hour including set up and switching between activities.
Study: NCT05314244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pylorus resecting pancreaticoduodenectomy
Description: The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
Study: NCT06509191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Melatonin 5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Melatonin 8 mg/day
Study: NCT06129617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: 5 treatments with hemodialysis on day 1, 2, 3, 5 and 7

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADVOS
Description: 5 treatments with ADVOS on day 1, 2, 3, 5 and 7
Study: NCT06288464

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Fibre
Description: Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
Study: NCT06153680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.
Study: NCT05879094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morton extension
Description: A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
Study: NCT05901389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Study: NCT06509191

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT05935761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator arms, except placebo dispensed
Study: NCT06576921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With Chemotherapy
Description: Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo combined with Chemotherapy
Description: Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
Study: NCT04638946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Titration to high intensity exercise (T-HIE)
Description: All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate \[220-age\] - resting heart rate)\*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise prescription
Description: All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate \[220-age\] - resting heart rate)\*30-39% (lower/upper limit of zone) - resting heart rate.
Study: NCT05775965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: Rivaroxaban 10mg daily for 35 days post hip fracture surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA) 81mg Oral Tablet
Description: acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
Study: NCT06112743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study: NCT06469944

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Tirumotecan (sac-TMT)
Description: Administered via IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered via oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered via oral tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Administered via IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: Administered via IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered via IV infusion
Study: NCT06399653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (active comparator)
Description: Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (sham comparator)
Description: Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
Study: NCT06491914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg
Description: Administered by intravitreal (IVT) injection
Study: NCT05776004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL02
Description: CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological 0.9% sodium chloride solution for iv administration
Study: NCT04985487

Intervention type: OTHER
Intervention: brolucizumab
Description: Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05723809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussive Therapy Device
Description: Same as group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Same as group description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Same as group description
Study: NCT05926479

Intervention type: OTHER
Intervention: Translating the Questionnaire into Turkish and Related Processes
Description: The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.

Intervention type: OTHER
Intervention: Validity
Description: The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.

Intervention type: OTHER
Intervention: Reliability
Description: The reliability of the materials will be tested with Cronbach alpha.
Study: NCT05594472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozonated olive oil
Description: Topical treatment will be applied for 5 consecutive days on the erosions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical garamycin cream
Description: Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
Study: NCT06218680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
Study: NCT00995059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally
Study: NCT06079645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
Description: Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of triamcinolone acetonide (40 mg/ml) with needles
Description: Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
Study: NCT04271332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: Arbaclofen tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Manufactured to match Arbaclofen in size, shape, color and taste